Capricor Therapeutics, INC Form 4 insider transactions

Capricor Therapeutics, Inc. reports a Form 4 filing detailing stock transactions by EVP, General Counsel Karen Krasney.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, has sold a significant number of company shares through a pre-arranged trading plan.

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, Inc., reported transactions involving the purchase and sale of company common stock, executed under a Rule 10b5-1 trading plan.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, reported transactions involving the purchase and sale of company common stock and stock options.

Capricor Therapeutics' Chief Commercial Officer Michael T. Maurer received 80,000 stock options with an exercise price of $29.36.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, acquired 3,000 shares of common stock on May 18, 2026, at a price of $1.39 per share.

Director Frank Litvack of Capricor Therapeutics acquired 3,937 shares of common stock for $1.39 per share, increasing his direct holdings.

Capricor Therapeutics, Inc. reports a Form 4 filing detailing stock transactions by EVP, General Counsel Karen Krasney.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, has sold 25,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Capricor Therapeutics Director Karimah Es Sabar reported a sale of 7,529 shares of common stock on April 2, 2026, executed under a pre-established 10b5-1 trading plan.

Capricor Therapeutics' EVP and General Counsel, Karen Krasney, reported the exercise of stock options and subsequent sale of common stock totaling 25,000 shares under a Rule 10b5-1 trading plan.

Capricor Therapeutics Director Karimah Es sold over $3.5 million worth of shares after exercising stock options under a pre-arranged 10b5-1 plan.

Capricor Therapeutics CFO Anthony Bergmann exercised stock options and subsequently sold 25,000 shares under a pre-arranged trading plan.

Karen Krasney, Capricor Therapeutics' EVP and General Counsel, exercised 2,500 stock options at $1.39 per share, increasing her direct beneficial ownership to 30,547 common shares.

Capricor Therapeutics CEO Linda Marban was granted 150,000 stock options and 7,500 restricted stock units on January 5, 2026, as part of her annual equity compensation.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, received significant equity grants, including stock options and restricted stock units, with some vesting contingent on FDA approval of Deramiocel.

Capricor Therapeutics' EVP and General Counsel, Karen Krasney, was granted 45,000 stock options with varying vesting schedules.

Capricor Therapeutics director Paul Gisbert Auwaerter received grants of stock options totaling 22,280 shares with an exercise price of $24.81.

Capricor Therapeutics director Mike Kelliher was granted 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Capricor Therapeutics Director Philip J. Gotwals was granted 15,500 stock options with an exercise price of $24.81, vesting monthly through 2026.

Capricor Therapeutics director Karimah Es Sabar was granted 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Capricor Therapeutics director David B. Musket received a grant of 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Capricor Therapeutics director George W. Dunbar Jr. was granted 15,500 stock options with an exercise price of $24.81 for annual board service.

Capricor Therapeutics Director Frank Litvack was granted 50,000 stock options with an exercise price of $24.81, vesting monthly over 2026.

Capricor Therapeutics director George W. Dunbar Jr. reported an option exercise for 3,000 shares, but the transaction date appears after the option's stated expiration.

Linda Marban, CEO of Capricor Therapeutics, reports the acquisition and disposal of common stock and derivative securities.

Anthony Bergmann, CFO of Capricor Therapeutics, exercised stock options to acquire 2,500 shares of common stock at $1.39 per share on March 3, 2025.

Frank Litvack, a director at Capricor Therapeutics, exercised stock options to acquire 25,000 shares and disposed of 2,543 shares to cover the exercise price.

Director George W. Dunbar Jr. exercised stock options to acquire 750 shares of Capricor Therapeutics at $1.39 per share.

Director Earl M. Collier Jr. exercised stock options to acquire 750 shares of Capricor Therapeutics common stock at $1.39 per share.